Replies to post #84879 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

OK, here is the quote:

So in reality, I think, you know, what we’re really comparing now is actually early DC vaccinations versus later DC vaccinations

The "early vs late" clearly refers to the OS secondary.

The PI for the trial stated clearly that what they are really looking at now is the secondary endpoint.

Furthermore, she places the "not reached" statement within two paragraphs or so of discussion of OS and crossover. Kind of odd when PFS events would not be effected by this. I guess she was just sloppy, but that would be an odd character trait for a brain surgeon.

And please drop the strawman points. I never claimed she said anything about PFS results, or that OS was the only thing being looked at.

[pgsd]

Great post RK:]

[doingmybest]

Rkmatters, do you recall off the top of your head which abstract mentioned the 5 month PFS advantage? Don't go to trouble for it, thx.

[antihama]

OK, I may get slammed for this post but why can’t this trial receive conditional approval for rGBM too? Longs are hoping for AA in newly diagnosed GBM with PFS1 and full approval in ndGBM when OS comes to maturation but at crossover pts will be getting dosed again so they could possibly get statistically significant data (mesenchymal?) OS data from that. At crossover, there will be no placebo to compare to so that’s why I’m thinking AA only. They would then have to run a placebo controlled trial in rGBM to get full approval.

Happy Thanksgiving to all…and to those w upcoming birthdays, Happy Birthday. :)